HIV Tx Guidelines 2023

HIVTxGuidelines2023_Theme_Banner_720px_v3

About the Program

Target Audience
Learning Objectives
Faculty
Joint Accreditation Statement
Credit Designation
Disclosure of Conflicts of Interest
Method of Participation and Request for Credit
Disclosure of Unlabeled Use
Disclaimer
Computer System Requirements

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

Describe HIV epidemiologic and demographic trends that form the basis for HIV prevention and testing guidelines
Apply major guidelines to the identification of individuals at risk for HIV infection and to determine the appropriateness of using PrEP in individual patients
Describe research findings that support current HIV treatment guidelines
Provide effective antiretroviral therapy to a variety of different patient types based on HIV treatment guidelines

Release Date: May 24, 2023

Expiration Date: May 24, 2024

Media: Internet

Estimated time to complete each Module: 30 minutes

Back to Top

Faculty

Michelle Cespedes, MD Associate Professor of Medicine, Division of Infectious Diseases The Mount Sinai Hospital New York, New York	Helena Kwakwa, MD Director of HIV Clinical Services Philadelphia Department of Public Health Ambulatory Health Services Philadelphia, Pennsylvania
Paul Sax, MD Clinical Director Division of Infectious Diseases Brigham and Women's Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts	Renslow Sherer, MD Professor of Medicine Section of Infectious Diseases and Global Health University of Chicago Chicago, Illinois

Back to Top

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Back to Top

Credit Designation

Physician Continuing Medical Education and Continuing Pharmacy Education

Case 1 (HIV Prevention Options):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine designates this continuing medical education activity for .50 contact hour(s)(0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: UAN JA4008162-9999-23-220-H01-P
Type of Activity: Knowledge

Case 2 (PrEP Initiation):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 3 (Potential Switch to Long-Acting ART):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRAPRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 4 (Stable Switch):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 5 (HIV and Pregnancy):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 6 (Aging with HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 7 (Barriers to PrEP):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 8 (HIV Resistance and Drug Interactions):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 9 (Barriers to Oral ART):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Case 10 (Stable Switch in 53-Year-Old Man):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:

Michelle Cespedes, MD

Consultant/Advisory Board: ViiV, Gilead

Helena Kwakwa, MD

Grant/Research Support: ViiV (relationship ended)

Paul Sax, MD

Grant/Research Support: Gilead, GSK/ViiV
Consultant/Advisory Board: Gilead, GSK/ViiV, Merck, Janssen
Other (Editorial Boards): Clinical Infectious Diseases, UpToDate, NEJM Journal Watch

Renslow Sherer, MD

Grant/Research Support: Gilead

The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose

Back to Top

Method of Participation and Request for Credit

1) Go to http://www.cmeuniversity.com/

2) Login or Create a New Account (will take less than 1 minute)
   a) If you receive a message when creating a new account that "the email you entered is already in use", please click the Forgot my Username or Password link to have your Username and Password sent to you via email
   b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 17944 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) (If applicable) Complete the Post-test
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files
9) For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.